Novartis Pulls Galvus From Germany After Failed Price Negotiations
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis has withdrawn its oral anti-diabetic Galvus from the German market after failing to secure a mutually beneficial price with payers. Galvus is the only drug dropped from reimbursement under a since-repealed policy to assess added benefits of brand drugs marketed before 2011.
You may also be interested in...
German Pricing Plan Avoids Terrible Twos, But More Growing Pains Ahead
In the two years since Germany’s reimbursement process for new drugs turned Europe’s largest market into one of the toughest, the impact on pricing hasn’t been as bad as many expected. But there’s more to come, with several on-market categories slated for retrospective review, and even mandatory rebates could follow.
Germany's Health Reform Law Stumbles Through Parliament
Measure will curtail manufacturer latitude on drug pricing, especially for new drugs not shown to have added benefit over existing products.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.